Please assess the completion status of the following clinical trial:

Trial Title: Cannabis Extract in Refractory Epilepsy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of epilepsy according to the ILAE classification.~* At least 4 motor seizures per month at the start of the study, despite treatment with at least two different anti-epileptic drugs (given concurrently or sequentially) for at least one year.~* At least 4 motor seizures per month during the prospective baseline phase (4 weeks) with no 21-day seizure free periods.~* Stable dose(s) of the same AED(s) for one month prior to screening.~* Agrees not to take any cannabinoids during the study or any other investigational compound for one month before the study or outside cannabinoids during the study.~* Is planning to stay in Canada for the duration of the trial.~* Is able to travel to one of the study sites for in-person visits with the study physicians and to a local lab for blood collection.~* Has access to telephone, computer, and internet for regular correspondence and to complete the study questionnaires.~Exclusion Criteria:~* Participation in a study involving administration of an investigational compound within one month of Visit 1.~* Evidence of clinically significant non-epileptic disease (cardiac, respiratory, gastrointestinal, hepatic, hematologic, or renal disease, etc.) that in the opinion of the investigators could affect the patient's safety or trial conduct.~* Progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors.~* Occurrence of psychogenic seizures in the previous year.~* History of drug misuse/abuse (other than cannabinoids). Consideration may be given to allowing inclusion of subjects with remote history of drug abuse (within a defined relevant time period).~* Multiple drug allergies (dermatological, hematological, or organ toxicity) or more than one severe drug reaction(s).~* Pregnancy, breastfeeding.~* Known or suspected hypersensitivity to cannabinoids, or any of the excipients of the investigational medicinal product.~* Patients with a history of major depression, suicidal ideation or attempted suicide, schizophrenia or any other psychotic disorder, patients with a family history of schizophrenia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medical cannabis (Type: EXPERIMENTAL): Capsules containing cannabis extract, dissolved in high-oleic sunflower oil, and CBD/THC in a 16:1 ratio.
- Placebo Control (Type: PLACEBO_COMPARATOR): Capsules containing a high-oleic sunflower oil, calorie-equated to the active treatment. There will be no active compounds in the placebo treatment.~Following treatment with placebo, all participants in this group will begin treatment with medical cannabis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy